|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-7-19
|
|
pubmed:abstractText |
Satraplatin is an orally available platinum analog. The purpose of this study was to better characterize satraplatin's preclinical antitumor efficacy in a variety of sensitive and resistant human tumor cell lines and in a prostate cancer xenograft model and to evaluate the effect of satraplatin on PSA expression and/or secretion in a prostate cancer cell line.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
589-600
|
|
pubmed:meshHeading |
pubmed-meshheading:17541592-Administration, Oral,
pubmed-meshheading:17541592-Animals,
pubmed-meshheading:17541592-Antineoplastic Agents,
pubmed-meshheading:17541592-Cell Line, Tumor,
pubmed-meshheading:17541592-Cell Proliferation,
pubmed-meshheading:17541592-Drug Resistance, Neoplasm,
pubmed-meshheading:17541592-Humans,
pubmed-meshheading:17541592-Male,
pubmed-meshheading:17541592-Mice,
pubmed-meshheading:17541592-Mice, Nude,
pubmed-meshheading:17541592-Organoplatinum Compounds,
pubmed-meshheading:17541592-Prostate-Specific Antigen,
pubmed-meshheading:17541592-Prostatic Neoplasms,
pubmed-meshheading:17541592-Xenograft Model Antitumor Assays
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Preclinical antitumor activity of the oral platinum analog satraplatin.
|
|
pubmed:affiliation |
From GPC Biotech, Fraunhoferstrasse 20, 82152 Martinsried/Munich, Germany. Katja.wosikowski@gpc-biotech.com
|
|
pubmed:publicationType |
Journal Article
|
